Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Sihuan Pharmaceutical Holdings Group EV-to-EBIT?
Sihuan Pharmaceutical Holdings GroupSHPHF 60 EV-to-EBIT is 8.29 as of Jul. 27, 2026, which is 44% above its 10-year median of 5.75. GuruFocus rates SHPHF with a GF Score™ of 60/100 and a GF Value™ of $0.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 690 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks better than 77.68% on this metric.
Sihuan Pharmaceutical Holdings Group (OTCPK:SHPHF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sihuan Pharmaceutical Holdings Group's Enterprise Value for the quarter that ended in Dec. 2025 was $1,174.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sihuan Pharmaceutical Holdings Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $87.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group EV-to-EBIT Related Terms
Sihuan Pharmaceutical Holdings Group EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group EV-to-EBIT Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sihuan Pharmaceutical Holdings Group EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's EV-to-EBIT falls into.
Sihuan Pharmaceutical Holdings Group's current Enterprise Value is $722.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sihuan Pharmaceutical Holdings Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $87.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group (SHPHF) has a EV-to-EBIT of 8.29 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. This is 44% above median its historical median of 5.75. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #154 out of 690 companies in the Drug Manufacturers industry, placing it in the top 22.3%.
Is Sihuan Pharmaceutical Holdings Group's EV-to-EBIT too high?
Sihuan Pharmaceutical Holdings Group's current EV-to-EBIT of 8.29 is 44% above median its 10-year median of 5.75. The Drug Manufacturers industry median EV-to-EBIT is 15.50. Sihuan Pharmaceutical Holdings Group's value of 8.29 is 46.5% below this industry median. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #154 out of 690 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #154 out of 690 companies for EV-to-EBIT. This places Sihuan Pharmaceutical Holdings Group in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.50. Sihuan Pharmaceutical Holdings Group's value of 8.29 is 46.5% below this benchmark. While the company's 10-year median is 5.75 vs. the industry median of 15.50, Sihuan Pharmaceutical Holdings Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current EV-to-EBIT of 8.29 is 46.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current EV-to-EBIT is 8.29, which is 44% above median its own 10-year median of 5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.16, compared to a current price of $0.12 — trading 25% below its estimated fair value. The current EV-to-EBIT is 8.29, which is 44% above median its 10-year median of 5.75 and 46.5% below the Drug Manufacturers industry median of 15.50. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current EV-to-EBIT is 8.29 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of $0.12 is trading 25% below its estimated GF Value™ of $0.16.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.
Key valuation signals for SHPHF:
EV-to-EBIT: 8.29 (44% above median its 10-year median of 5.75)
GF Value™: $0.16 vs. price of $0.12 (25% below fair value)
Industry Position: 46.5% below the Drug Manufacturers median (#154 of 690)
No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Business Description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
60GF Score
Get the complete analysis for SHPHF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPHF has been successfully added to your 
